





# Current myositis clinical trials and tribulations

Didem Saygin <sup>1</sup>, Victoria Werth,<sup>2</sup> Julie J Paik <sup>3</sup>, Jin Kyun Park <sup>4</sup>,  
Merrilee Needham,<sup>5</sup> Ingrid E Lundberg <sup>6</sup>, Lisa Christopher-Stine<sup>3</sup>

**Handling editor** Josef S Smolen

<sup>1</sup>Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

<sup>2</sup>Department of Dermatology, Perelman School of Medicine, University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA

<sup>3</sup>Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA

<sup>4</sup>Department of Internal Medicine, Division of Rheumatology, Seoul National University Hospital and College of Medicine, Seoul, Korea (the Republic of)

<sup>5</sup>Department of Neurology, Fiona Stanley Hospital, IiD Murdoch University and University of Notre Dame, Perth, Western Australia, Australia

<sup>6</sup>Department of Medicine, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

## Correspondence to

Dr Didem Saygin, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15260, USA; didemsaygin4@gmail.com and Dr Lisa Christopher-Stine, Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA; lchrist4@jhmi.edu

Received 30 June 2023  
Accepted 30 December 2023  
Published Online First  
12 January 2024



© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Saygin D, Werth V, Paik JJ, et al. *Ann Rheum Dis* 2024;**83**:826–829.

## ABSTRACT

With improved understanding of disease pathogenesis and availability of outcome measures, there has been a remarkable increase in the number of therapeutic clinical trials in idiopathic inflammatory myopathies (myositis) over the last three years reaching as many as five trials per site. These trials share similar design and inclusion/exclusion criteria resulting in a competitive clinical trial landscape in myositis. While these are exciting times for the myositis field, we have a number of concerns about the design and conduct of the myositis trials. These include competitive landscape, lengthy placebo arms, underrepresentation of minority groups among participants, use of patient reported outcome measures with limited/no data on validity in myositis, antiquated disease classification criteria, and unclear performance of the ACR/EULAR Myositis Response Criteria in skin-predominant patients despite inclusion of these patients in trials. In this viewpoint, we further discuss these concerns and offer potential solutions such as including patient perspectives in the trial design and adoption of innovative frameworks.

Idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous autoimmune diseases including dermatomyositis, polymyositis, anti-synthetase syndrome, immune-mediated necrotising myopathy and inclusion body myositis (IBM). There are currently three therapies approved by the US Food and Drug Administration (FDA), while intravenous immunoglobulin is the only one approved based on a placebo controlled randomised trial.<sup>1,2</sup> With improved understanding of the disease pathogenesis and availability of outcome measures with adequate measurement properties, there has been a dramatic increase in the number of myositis therapeutic clinical trials over the last 3 years (table 1). While an expanding list of potential therapeutic options with various different mechanisms of action for patients with myositis represents a time of excitement and hope, this enthusiasm should be tempered given several concerns with regard to the conduct of current myositis clinical trials.

## A COMPETITIVE CLINICAL TRIALS LANDSCAPE IN A RARE DISEASE

There are currently as many as five simultaneous active myositis therapeutic trials with similar inclusion/exclusion criteria being conducted at several participating sites resulting in a competitive clinical trial landscape in myositis which raises concerns for recruitment. To our knowledge, this is the largest number of industry-sponsored myositis clinical trials to date that are recruiting simultaneously with a total recruitment goal of 1427 patients (table 1). Although inability to reach recruitment goals may

lower the enthusiasm to conduct trials in this rare disease, these trials are conducted simultaneously at numerous centres across the world with the goal of improving recruitment rates. To better address this, different trial designs should strongly be considered: (1) adaptive clinical trial designs in which the number of participants is continually refined based on interim data results and (2) platform trials that test multiple drugs in parallel under a single protocol. Harmonising the regulatory requirements of concurrent trials under a single infrastructure and using a shared, common placebo arm with these innovative trial designs could significantly decrease the patient burden, increase participation, reduce the cost and administrative burden on the investigators and coordinators, and ultimately expedite drug discovery in IIM. In fact, platform trials have been highly successful in other rare diseases such as amyotrophic lateral sclerosis (ALS) and could be particularly relevant to myositis given that the inclusion/exclusion criteria, endpoints and design across the current trials are similar.<sup>3</sup> Further, in our experience, one of the major patient-reported barriers to trial participation is potential assignment to the placebo arm. This concern is magnified in instances when the placebo arm is mandated to be lengthy by the FDA due to perceived safety concerns with novel agents. Platform trials with several arms and open-label extensions after study completion increase the chance of patients to receive novel therapies. Specifically, when a phase III trial is pursued following a phase II trial, it would be helpful to have the option to continue the study drug until the phase III trial is completed if the study drug has benefited the patient. Despite these benefits, platform trials are not attractive to stakeholders due to operational complexities and their high cost requiring an integrated funding model with multiple partners.<sup>4</sup> However, these challenges can be overcome through independent organisations that can coordinate buy-in and engagement between multiple stakeholders and provide a centralised governance structure (such as the new organization named Myositis International Health and Research Collaborative Alliance [MIHRA]). Strong research networks and active patient advocacy organisations facilitated the successful implementation of the platform trials in ALS which can be emulated in myositis.<sup>3</sup>

## DIVERSITY, EQUITY AND INCLUSION RECRUITMENT BARRIERS AND THE USE OF DECENTRALISED TRIAL DESIGNS

Black people and Hispanics/Latinos traditionally constitute <5% of participants in myositis therapeutic trials despite the reported more severe

**Table 1** Industry sponsored, active, multicenter myositis clinical trials (excluding inclusion body myositis) that are recruiting adult participants (obtained from ClinicalTrials.gov)

Study drug (route)	Key inclusion criteria	Primary endpoint(s)	Estimated enrolment target	Design	Treatment duration
Brepocitinib (PO)	Active muscle AND skin disease (DM)	Total improvement score	225	Phase III, double-blind, placebo controlled RCT	52 weeks
Efgartigimod PH20 (SC)	Active muscle disease (DM, JDM, PM, IMNM)	Total improvement score	240	Phase II/III, double-blind, placebo controlled RCT	Phase II: 24 weeks Phase III: 52 weeks
Enpatoran (PO)	Active muscle disease (DM, PM)	Total improvement score, adverse events, change in vitals	40	Phase IIa, double-blind, placebo controlled RCT	24 weeks
GLPG3667 (PO)	Active muscle disease (DM)	Percentage of patients with at least minimal improvement in Myositis Response Criteria	62	Phase II, double-blind, placebo controlled RCT	24 weeks
Immunglobulin Pro20 (SC)	Active muscle disease OR rash (DM)	Responder rate (at least minimal improvement in Myositis Response Criteria)	126	Phase III, double-blind, placebo controlled RCT	24 weeks
Nipocalimab (IV)	Active DM, IMNM, ASyS	Percentage of patients with at least minimal improvement in Myositis Response Criteria and prednisone $\leq$ 5 mg/daily	200	Phase II, double-blind, placebo controlled RCT	52 weeks
Ravulizumab (IV)	Active DM	Percentage of patients with at least moderate improvement in Myositis Response Criteria	150	Phase II/III, double-blind, placebo controlled RCT	50 weeks
PF-06823859 (anti-interferon beta therapy; IV)	Active DM or PM	At least moderate improvement in Myositis Response Criteria	270	Phase III, placebo controlled RCT	52 weeks
Daxdilimab (SC)	Active muscle disease (DM, ASyS)	Total improvement score	96	Phase II, placebo controlled RCT	44 weeks
Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201; IV)	Active muscle disease (DM, ASyS, IMNM)	Adverse events	18	Phase I/II, open label single arm trial	Single infusion

ASyS, anti-synthetase syndrome; DM, dermatomyositis; IMNM, immune-mediated necrotising myopathy; IV, intravenous; JDM, juvenile dermatomyositis; PM, polymyositis; PO, per oral; RCT, randomised controlled trial; SC, subcutaneous.

disease course and differences in clinical manifestations in these patients.<sup>15-7</sup> The limited diversity in myositis clinical trials could result from several barriers including trial availability as well as access and enrolment practices requiring participants from underserved communities to travel to large academic centres for clinical trials which may not be plausible due to costs, time constraints and functional disability observed in approximately one in four patients with IIM.<sup>8</sup> Trial participation requires significant time commitment and financial resources due to missed workday and out-of-pocket costs related to travel. Direct and indirect costs of participation and transportation are among the most commonly reported barriers to clinical trial participation among under-represented minorities.<sup>9</sup> Therefore, appropriate compensation of participants needs to be carefully addressed by the investigators and the FDA.

Enhancing diversity in trials could also be achieved by adopting fully or hybrid decentralised clinical trials (DCTs). DCTs involve using digital health technologies to conduct telehealth visits at patients' homes or local healthcare facilities. By eliminating the need for travel and reducing patient costs, DCTs hold immense potential to meet recruitment goals and to facilitate participation of individuals with disabilities, older adults and minority groups from underserved areas in trials. However, these trials often require additional training of the study personnel, several contracted services and careful coordination of activities by the local sites. Thus, participating sites should be appropriately compensated to support the new infrastructure required for these trials. Recognising the value in DCTs, the FDA also recently published a draft guidance document.<sup>10</sup> While this is an excellent first step, there are potential obstacles. Sponsors are required to adhere to all pertinent local laws, regulations and licensing requirements related to medical practice, drug supply chain and dispensing and intellectual property administration

when executing a DCT. This may require navigating complex and changeable laws across multiple US states. However, these challenges can be mitigated by early engagement with the regulatory bodies during trial design.<sup>11</sup> In fact, a recent myositis-associated interstitial lung disease trial (NCT05335278) adopts DCT design which will provide an opportunity to examine the feasibility of such trials in IIM.

#### PATIENT-REPORTED OUTCOMES AND PATIENT-CENTRIC RESEARCH CHALLENGES

Design of diverse, patient-centric trials not only requires tackling barriers for enrolment but also incorporating reliable and valid patient-reported outcome measures assessing symptoms that matter most to patients with IIM and are available and validated in multiple languages. Despite the extensive body of work on patient-reported outcome measures, some trials use measures that have not been adequately studied in IIM. A decade of work of the Outcome Measures in Rheumatology (OMERACT) Myositis Working Group with patient focus groups in the USA, South Korea, the Netherlands and Sweden demonstrated these symptoms as physical function, pain interference and fatigue<sup>12-14</sup> and determined the instruments as PROMIS Physical Function (8b), Pain Interference (6a) and Fatigue (7a) to best capture these symptoms.<sup>15</sup> The evidence towards reliability, validity and responsiveness of these patient-reported outcome measures has been demonstrated in a large international cohort of patients from Australia, the Netherlands, Sweden, South Korea and the USA (in English, Dutch, Swedish and Korean) supporting their use as clinically meaningful patient-reported outcome measures in myositis trials recruiting participants from across the world.<sup>16</sup> For patients with skin-predominant disease, additional validated skin-directed quality of life measures should also be considered.<sup>17</sup>

### ANTIQUATED CLASSIFICATION CRITERIA

In 2017, the European Alliance of Associations for Rheumatology and American College of Rheumatology (EULAR/ACR) Classification Criteria for adult and juvenile IIM were developed with a data-driven approach classifying the IIM subgroups of dermatomyositis, amyopathic dermatomyositis, IBM, polymyositis and juvenile dermatomyositis.<sup>18</sup> With the discovery of new autoantibodies in IIM associated with distinct clinicopathological phenotypes over the years, new IIM subtypes emerged including immune-mediated necrotising myopathy and anti-synthetase syndrome, and polymyositis is now recognised to constitute only a minority of the patients with IIM.<sup>19</sup> However, some trials continue to enrol patients with polymyositis which raises concern for generalisability of these results in real-world clinical practice. Further, lack of recognition of newer IIM subtypes hampers the ability to accurately classify these patients in the clinical trials. Revision of the current EULAR/ACR Myositis Classification Criteria can help better define newly recognised IIM subtypes for inclusion in the clinical trials and is currently underway.

### HETEROGENEITY OF DISEASE PRESENTATION AND EXPRESSION INCLUDING SKIN-DOMINANT DISEASE

The ACR/EULAR Myositis Response Criteria is a composite measure that is commonly used as primary endpoint in myositis clinical trials and reflects changes in six myositis core set measures.<sup>20</sup> These core set measures are Patient and Physician Reported Global Disease Activity, Health Assessment Questionnaire Disability Index, Extramuscular Global Disease Activity, manual muscle testing and muscle enzymes. Even though the majority of myositis clinical trials only enrol patients with active muscle disease, some trials allow for recruitment of patients with amyopathic/hypomyopathic disease as well. Prior studies suggest that the ACR/EULAR Myositis Response Criteria may not perform as well in patients with skin-predominant disease.<sup>21–22</sup> Therefore, further studies are required to understand the performance of the criteria in patients with skin-predominant disease.

In a relatively rare disease, it is also important to have a sensitive validated tool that captures meaningful change in skin disease from a patient perspective. The investigator global assessment (IGA) is often the preferred outcome measure by the regulatory agencies to assess improvement in skin disease. However, despite the validation and extensive use of IGA in psoriasis, it was only recently developed for dermatomyositis and failed to consistently discriminate between no and slight levels of improvement in a dermatomyositis clinical trial.<sup>22</sup> On the other hand, the Cutaneous Dermatomyositis Disease Area and Severity Index is a dermatomyositis-specific validated outcome measure and demonstrated a better sensitivity to change than IGA.<sup>22–24</sup> Acceptance of this measure by regulatory agencies would allow studies that target a large group of patients with amyopathic disease, expanding the therapeutic options for these severely impacted patients.

In summary, the competitive nature of the current myositis clinical trial landscape necessitates a more efficient and patient-focused approach. This can be achieved by (1) including patient perspectives in the trial design and execution, (2) using reliable and valid patient-reported outcome measures, (3) using enrichment strategies to actively promote diversity in recruitment, and (4) employing innovative trial frameworks like adaptive trial designs and DCTs when suitable. For optimal design of myositis clinical trials, it will be important to revise the EULAR/ACR Myositis Classification Criteria to include newer IIM subtypes,

as well as to evaluate the performance of the ACR/EULAR Myositis Response Criteria in patients with predominantly skin-related disease.

**Contributors** Conceptualisation—DS and LC-S. Writing (original draft)—DS and LC-S. Review and editing—all authors.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** DS, JKP, MN, IEL, and LCS are members of the OMERACT Myositis Working Group. JJP received funding from NIAMS (K23AR073927); grants from Pfizer Inc, CORBUS, Kezar, Priovant and EMD Serono; royalty from Uptodate; and consulting fees from Pfizer, Kezar, Alexion, EMD Serono, Priovant and Guidepoint Inc. IEL received support from Swedish Research Council; consulting fees from Corbus Pharmaceutical, EMD Serono, ArgenX, Pfizer, Galapagos, Bristol Myers Squibb and Chugai; honoraria from Boehringer-Ingelheim; and currently holds stock in Roche and Novartis. MN received honorarium from Abcuro, Novartis, Sanofi-Aventis, Genzyme and Teva; participated on Data Safety Monitoring Board or Advisory Board for Abcuro, Teva and Sanofi-Genzyme; and received materials from Sanofi-Aventis. VW received grants from Pfizer, Corbus, CSL Behring, Priovant, Rome, Ventus and Horizon; received consulting fees from Pfizer, Janssen, Neovacs, Octapharma and CSL Behring; and University of Pennsylvania owns the copyright for the Cutaneous Dermatomyositis Disease Area and Severity Index. LCS received grants from Pfizer, Corbus, Kezar; royalties for IP related to anti-HMGCR assay from Inova Diagnostics; consulting fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, EMD Serono, ArgenX, Allogene, Pfizer, Horizon Therapeutics, Octapharma and NuVig; received payment for expert testimony from Bendin Sumrall and Ladner LLC, Feldman, Kleidman Coffey & Sappe LLP, Downs Ward Bender Hauptmann & Herzog, PA, Sulloway and Hollis, received support for attending meetings and travel from Octapharma and has patent with Inova Diagnostics/RDL.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

### ORCID iDs

Didem Saygin <http://orcid.org/0000-0003-1675-597X>

Julie J Paik <http://orcid.org/0000-0001-8436-1601>

Jin Kyun Park <http://orcid.org/0000-0003-2167-9393>

Ingrid E Lundberg <http://orcid.org/0000-0002-6068-9212>

### REFERENCES

- Aggarwal R, Charles-Schoeman C, Schessl J, *et al*. Trial of intravenous immune globulin in dermatomyositis. *N Engl J Med* 2022;387:1264–78.
- Aggarwal R, Charles-Schoeman C, Schessl J, *et al*. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("proderm study"). *Medicine (Baltimore)* 2021;100:e23677.
- Paganoni S, Berry JD, Quintana M, *et al*. Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. *Ann Neurol* 2022;91:165–75.
- Snowdon C, Kernaghan S, Moretti L, *et al*. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. *Trials* 2022;23:372.
- Schioppa E, Phillips K, MacDonald PM, *et al*. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. *Arthritis Res Ther* 2012;14:R22.
- Shamim EA, Rider LG, Pandey JP, *et al*. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between mesoamerican mestizos and North American caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum* 2002;46:1885–93.
- Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, *et al*. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-P17 and anti-P112 autoantibodies. *Rheumatology (Oxford)* 2017;56:999–1007.
- Opinc AH, Brzezińska OE, Makowska JS. Disability in idiopathic inflammatory myopathies: questionnaire-based study. *Rheumatol Int* 2019;39:1213–20.
- Ford JG, Howerton MW, Lai GY, *et al*. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. *Cancer* 2008;112:228–42.
- Administration USDoHaHSFaD. Decentralized clinical trials for drugs, biological products, and devices guidance for industry, investigators, and other stakeholders. Maryland FDA; 2023.
- Initiative CTT. Decentralized clinical trials; 2018.
- Alexanderson H, Grande MD, Bingham CO III, *et al*. Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 myositis special interest group. *J Rheumatol* 2014;41:581–92.

- 13 Park JK, Mecoli CA, Alexanderson H, *et al.* Advancing the development of patient-reported outcomes for adult myositis at OMERACT 2016: an International Delphi study. *J Rheumatol* 2017;44:1683–7.
- 14 Regardt M, Basharat P, Christopher-Stine L, *et al.* Patients' experience of Myositis and further validation of a myositis-specific patient reported outcome measure - establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12. *J Rheumatol* 2015;42:2492–5.
- 15 Esfandiary T, Park JK, Alexanderson H, *et al.* Assessing the content validity of patient-reported outcome measures in adult myositis: a report from the OMERACT myositis working group. *Semin Arthritis Rheum* 2020;50:943–8.
- 16 DiRenzo D, Saygin D, de Groot I, *et al.* Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: international study from the OMERACT myositis working group. *Semin Arthritis Rheum* 2023;58:152111.
- 17 Robinson ES, Feng R, Okawa J, *et al.* Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. *Br J Dermatol* 2015;172:169–74.
- 18 Lundberg IE, Tjärnlund A, Bottai M, *et al.* European league against rheumatism/ American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis* 2017;76:1955–64.
- 19 Loarce-Martos J, Lilleker JB, Parker M, *et al.* Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. *Rheumatology (Oxford)* 2021;60:3398–403.
- 20 Rider LG, Ruperto N, Pistorio A, *et al.* ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. *Rheumatology (Oxford)* 2017;56:1884–93.
- 21 Werth VBW, Dgetluck N, Hally K, *et al.* Efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis. EULAR; 2022. 106.
- 22 Pandya R, Dan J, Kleitsch J, *et al.* Validation of cutaneous dermatomyositis disease area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum phase 3 trial. *J Invest Dermatol* 2023;143:2378–85.
- 23 Ahmed S, Chakka S, Concha J, *et al.* Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. *Br J Dermatol* 2020;182:949–54.
- 24 Werth VP, Hejazi E, Pena SM, *et al.* Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. *J Invest Dermatol* 2022;142:2651–9.